Recombinant Encapsulated Cells Overexpressing Alpha-L-Iduronidase Correct Enzyme Deficiency in Human Mucopolysaccharidosis Type I Cells

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Cells Tissues Organs

• Publication date

  2011-07-19

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1159/000327532PMID 21778683
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of cryopreservation and hypothermic storage on cell viability and enzyme activity in recombinant encapsulated cells overexpressing alpha-L-iduronidase.

  2010cited by this paper
• Enzyme replacement therapy for the management of the mucopolysaccharidoses.

  2009cited by this paper
• Guidelines for the management of mucopolysaccharidosis type I.

  2009cited by this paper
• Enzyme replacement therapy for the management of the mucopolysaccharidoses.

  2009cited by this paper
• In vitro correction of ARSA deficiency in human skin fibroblasts from Metachromatic Leukodystrophy patients after treatment with microencapsulated recombinant cells

  2008cited by this paper
• Uptake of a recombinant human alpha-L-iduronidase (laronidase) by cultured fibroblasts and osteoblasts.

  2008cited by this paper
• An effective device for generating alginate microcapsules

  2008cited by this paper
• Upregulation of elastase proteins results in aortic dilatation in mucopolysaccharidosis I mice.

  2008cited by this paper
• Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression

  2008cited by this paper
• Uptake of a Recombinant Human α- L -Iduronidase (laronidase) by Cultured Fibroblasts and Osteoblasts

  2008cited by this paper
• Enzyme therapy in mannose receptor-null mucopolysaccharidosis VII mice defines roles for the mannose 6-phosphate and mannose receptors

  2006cited by this paper
• Bone marrow transplantation in patients with storage diseases: a developing country experience.

  2006cited by this paper
• Encapsulation cell therapy for mucopolysaccharidosis type VII using genetically engineered immortalized human amniotic epithelial cells.

  2006cited by this paper
• History, challenges and perspectives of cell microencapsulation.

  2004cited by this paper
• Neuroprotective Gene Therapy for Huntington's Disease, Using Polymer-Encapsulated Cells Engineered to Secrete Human Ciliary Neurotrophic Factor: Results of a Phase I Study

  2004cited by this paper
• Biodistribution, Kinetics, and Efficacy of Highly Phosphorylated and Non-phosphorylated β-Glucuronidase in the Murine Model of Mucopolysaccharidosis VII*

  2001cited by this paper
• El diagnóstico de enfermedades lisosomales hereditarias. Por morfología de células hematopoyéticas

  1997cited by this paper
• Expression of galectin-3 modulates T-cell growth and apoptosis.

  1996cited by this paper
• G2 cell cycle arrest induced by glycopeptides isolated from the bovine cerebral cortex

  1983cited by this paper
• A fluorometric assay using 4-methylumbelliferyl α-l-iduronide for the estimation of α-l-iduronidase activity and the detection of Hurler and Scheie syndromes

  1979cited by this paper
• A fluorometric assay using 4-methylumbelliferyl alpha-L-iduronide for the estimation of alpha-L-iduronidase activity and the detection of Hurler and Scheie syndromes.

  1979cited by this paper
• Bone marrow transplantation.

  1977cited by this paper

• Liposomal CRISPR/Cas9-Mediated Local Genome Editing for Joint Disease in Mucopolysaccharidosis Type I

  2026cites this paper
• Brain and visceral gene editing of mucopolysaccharidosis I mice by nasal delivery of the CRISPR/Cas9 system

  2022cites this paper
• Clinical Development of Cell Therapies to Halt Lysosomal Storage Diseases: Results and Lessons Learned.

  2021cites this paper
• Progressive eye pathology in mucopolysaccharidosis type I mice and effects of enzyme replacement therapy

  2020cites this paper
• Neonatal nonviral gene editing with the CRISPR/Cas9 system improves some cardiovascular, respiratory, and bone disease features of the mucopolysaccharidosis I phenotype in mice

  2019cites this paper
• Targeted enzyme delivery systems in lysosomal disorders: an innovative form of therapy for mucopolysaccharidosis

  2019cites this paper
• Optimization of alginate microcapsules containing cells overexpressing &agr;‐l‐iduronidase using Box‐Behnken design

  2018cites this paper
• Intra‐articular nonviral gene therapy in mucopolysaccharidosis I mice

  2018cites this paper
• Gene editing of MPS I human fibroblasts by co‐delivery of a CRISPR/Cas9 plasmid and a donor oligonucleotide using nanoemulsions as nonviral carriers

  2018cites this paper
• Enzyme replacement therapies: what is the best option?

  2018cites this paper
• In vivo genome editing of mucopolysaccharidosis I mice using the CRISPR/Cas9 system

  2018cites this paper
• Alginate-embedded HuH-7 cells increase MMP-9 and reduce OCLN expression in vitro

  2017cites this paper
• Factors influencing transfection efficiency of pIDUA/nanoemulsion complexes in a mucopolysaccharidosis type I murine model

  2017cites this paper
• Subcutaneous implantation of microencapsulated cells overexpressing α-L-iduronidase for mucopolysaccharidosis type I treatment

  2017cites this paper
• Comparative study of idursulfase beta and idursulfase in vitro and in vivo

  2016cites this paper
• Effects of Enzyme Replacement Therapy Started Late in a Murine Model of Mucopolysaccharidosis Type I

  2015influential citation
• PEGylated cationic nanoemulsions can efficiently bind and transfect pIDUA in a mucopolysaccharidosis type I murine model.

  2015cites this paper
• Cationic Nanoemulsions as a Gene Delivery System: Proof of Concept in the Mucopolysaccharidosis I Murine Model.

  2015cites this paper
• Gene delivery strategies for the treatment of mucopolysaccharidoses

  2014cites this paper
• Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice.

  2013cites this paper
• Chloramphenicol enhances IDUA activity on fibroblasts from mucopolysaccharidosis I patients.

  2013cites this paper
• Mucopolysacccharidoses: From understanding to treatment, a century of discoveries

  2012cites this paper
• Endocrine Disorders Emerging treatment options for the mucopolysaccharidoses

  2012cites this paper
• Emerging treatment options for the mucopolysaccharidoses

  2012cites this paper
• Intraperitoneal implant of recombinant encapsulated cells overexpressing alpha-L-iduronidase partially corrects visceral pathology in mucopolysaccharidosis type I mice.

  2012cites this paper
• Emerging treatment options for the mucopolysaccharidoses

  2012cites this paper
• Non viral gene transfer approaches for lysosomal storage disorders

  2011cites this paper